Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Debt Repayment
Cash used to repay borrowings during the period.
Maze Therapeutics, Inc.NASDAQ: MAZE
Debt Repayment · Q1 FY2026 · quarter ended Mar 2026
Debt repayment outflow grows to $38.52M
Q1 FY2026 debt repayment was $38.52M, compared with $0 a year earlier. Trailing-twelve-month debt repayment was $38.52M.
Context
- Debt repayment increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly debt repayment holds near $38.52M or moves back toward the trailing-twelve-month quarterly average of $9.63M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Debt Repayment history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Debt Repayment | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 24.48M | +51.3% |
| FY2023 | 2023-12-31 | 16.18M | — |
| FY2022 | 2022-12-31 | 0 | — |
Debt Repayment vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +342.0% is the 2nd highest of 7, against a peer median of -4.4%.
- Debt repayment amounts to 192.6% of revenue for MAZE, versus a peer median of 19.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $174.12M USD | +352.7% | — | 26.7% | |
| LTM Mar 2026 | $48.67M USD | -0.1% | — | 11.4% | |
| LTM Mar 2026 | $38.52M USD | +342.0% | — | 192.6% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $6M USD | +0.0% | — | 58.2% |
| FY2025 | €5.98M EUR | -130.0% | — | 133.4% | |
| LTM Jun 2026 | $1.61M USD | -208.1% | — | 0.2% | |
| LTM Mar 2026 | $10.03K USD | -8.8% | +18.6% | — | |
SEPNSepterna, Inc. | LTM Sep 2026 | $0 USD | — | — | 0.0% |
| Peer median (excluding MAZE) | — | -4.4% | +18.6% | 19.1% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.